SEQUENTIAL TREATMENT OF CANCER WITH 6-THIO-DG AND CHECKPOINT HIBITORS
Patent Information
- Application Number
- DE602021023612
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-13
- Filing Date
- 2021-03-12
- Publication Date
- 2024-12-18
- Estimated Expiration
- 2041-03-12
AI Technical Summary
Current immunotherapies for cancer, such as PD-L1/PD-1 checkpoint blockades, face challenges in effectively targeting tumors due to immune suppressive microenvironments and resistance mechanisms, necessitating the development of new approaches to enhance anti-tumor immune responses.
The use of 6-thio-2'-deoxyguanosine (6-thio-dG) in combination with immune checkpoint inhibitors like atezolizumab or cemiplimab, administered sequentially, to induce telomere stress and activate innate sensing pathways, thereby overcoming resistance and enhancing anti-tumor immunity.
This approach leads to significant inhibition of tumor growth, remission, reduction in tumor burden, and potential eradication of cancer cells, even in therapy-resistant cases, by leveraging telomere-targeted therapy and immune checkpoint inhibition.